Ananda Scientific announced today that it enrolled the first patient in a trial evaluating its Liquid Structure delivery system for treating PTSD.
In collaboration with the NYU Grossman School of Medicine, Ananda’s clinical trial will evaluate Nantheia A1002N5S, an investigational drug that uses cannabidiol (CBD) in Ananda’s proprietary Liquid Structure delivery technology to treat post-traumatic stress disorder (PTSD) symptoms, as well as neurocognitive impairment in those with PTSD and for PTSD comorbid with traumatic brain injury (TBI).
The Phase II double-blind, randomized, placebo-controlled eight-week study with adaptive dose design will evaluate Nantheia A1002N5S in 120 patients with PTSD, 50% of whom have comorbid mild TBI, according to a news release.
Nantheia A1002N5S (an oral product with 50 mg CBD per soft gel capsule) uses CBD in the Liquid Structure delivery technology, which makes cannabinoids and other plant-derived compounds highly bioavailable, water-soluble and shelf-life-stable.
“This is an important milestone for Ananda’s clinical development program, and we look forward to continuing to work with the NYU Grossman School of Medicine. We are impressed by the scientific rigor and professionalism of the NYU team in getting a cutting-edge program in place to test the efficacy of our very promising drug,” Ananda president Sohail R. Zaidi said in the release. “The initiation of patient enrollment in this study reinforces our commitment to our goal of improving health and wellness empowered by cannabinoid science. This is also an important step in our efforts to provide patients with PTSD with potentially improved therapeutic options.”
